RYR1 and myopathy: The role of anti-oxidants as a therapy in EHI/MHS is still to be fully studied; a recent clinical trial of N-acetylcysteine in patients with RYR1 related myopathy identified aberrant oxidative stress but treatment failed to show improvement in motor phenotypes or reduction of ROS51.